CBX3 predicts an unfavorable prognosis and promotes tumorigenesis in osteosarcoma
CBX3, namely chromobox protein homolog 3, a member of the heterochomatin protein 1 (HP1) family, has been shown to be associated with the tumorigenesis of various types of cancer. The aim of the present study was to assess the biological role and the clinicopathological importance of CBX3 in osteosa...
Gespeichert in:
| Veröffentlicht in: | Molecular medicine reports 2019-05, Vol.19 (5), p.4205-4212 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4212 |
|---|---|
| container_issue | 5 |
| container_start_page | 4205 |
| container_title | Molecular medicine reports |
| container_volume | 19 |
| creator | Ma, Chao Nie, Xing-Guo Wang, Yan-Li Liu, Xiang-Hua Liang, Xue Zhou, Qing-Lan Wu, Da-Peng |
| description | CBX3, namely chromobox protein homolog 3, a member of the heterochomatin protein 1 (HP1) family, has been shown to be associated with the tumorigenesis of various types of cancer. The aim of the present study was to assess the biological role and the clinicopathological importance of CBX3 in osteosarcoma. The Oncomine database was utilized to determine the CBX3 expression in sarcoma patients. A retrospective cohort study was conducted to evaluate the prognostic value of CBX3 expression. In addition, correlations between the clinicopathological features of the osteosarcoma patients and CBX3 expression were assessed and involved recurrence, distant metastasis, lymph node metastasis, response to chemotherapy, pathological differentiation, clinical stage, anatomic location, tumor size and age. To investigate the function of CBX3 in osteosarcoma, a small interfering RNA for CBX3 was designed and this was used for the transfection of osteosarcoma MG63 cells. Then, the effects of CBX3 on proliferation, cell cycle distribution and apoptosis of osteosarcoma cells were investigated via CCK‑8 assay and cell cycle assay and cell apoptosis analysis, respectively. Based on our findings, upregulation of CBX3 expression was noted both in osteosarcoma and also other sarcoma types, which included pleomorphic liposarcoma, myxofibrosarcoma, myxoid/round cell liposarcoma and dedifferentiated liposarcoma. In addition, based on the retrospective cohort study, CBX3 expression was associated with the disease‑free survival (DFS) and overall survival (OS) of the osteosarcoma patients and a large tumor size, high distant metastasis rate and high clinical stage rate. In addition, the proliferation ability was blocked by the knockdown of CBX3 through the application of CBX3 siRNA, and CBX3 knockdown also led to increased apoptosis and cell cycle arrest at G0 and G1 phases in osteosarcoma cells. CBX3 is highly expressed in human osteosarcoma tissues. Meanwhile, high CBX3 is a predictor of the poor prognosis of osteosarcoma patients. To conclude, the growth of osteosarcoma can be promoted by CBX3, which may be used as an independent potential prognostic biomarker for patients suffering from osteosarcoma. |
| doi_str_mv | 10.3892/mmr.2019.10104 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6470990</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A585448577</galeid><sourcerecordid>A585448577</sourcerecordid><originalsourceid>FETCH-LOGICAL-c551t-72d8451d982c585508e4c9f7a75afae996513196c2137efc1f24aa7982e0b3183</originalsourceid><addsrcrecordid>eNptksuLFDEQxoO4uA-9epQGL15mzLOTXITdwVVhYVlQ8BYy6cqYpZOMSfeC_71pd1wfLDkkVfWrL1TyIfSS4DVTmr6NsawpJnpNMMH8CTohUpMVw5g_PZyp1vIYndZ6i3EvqNDP0DHDmlNO5Qm62Vx8Zd2-wBDcVDubujl5e5eL3Y7Q8nmXcg1LYViimCeo3TTHXMIOEiylkLpcJ8jVFpejfY6OvB0rvDjsZ-jL5fvPm4-rq-sPnzbnVysnBJlWkg6KCzJoRZ1QQmAF3GkvrRTWW9C6F4QR3TtKmATviKfcWtlwwFtGFDtD7-519_M2wuAgTcWOZl9CtOWHyTaYfyspfDO7fGd6LrHWuAm8OQiU_H2GOpkYqoNxtAnyXA2lmPa9wj1p6Ov_0Ns8l9TGaxQhVBGs2B9qZ0cwIfnc7nWLqDlvI3KuhJSNWj9CtTVADC4n8KHlH2twJddawD_MSLBZTGCaCcxiAvPLBK3h1d8v84D__nX2EwzNrGA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2211281083</pqid></control><display><type>article</type><title>CBX3 predicts an unfavorable prognosis and promotes tumorigenesis in osteosarcoma</title><source>Spandidos Publications Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Ma, Chao ; Nie, Xing-Guo ; Wang, Yan-Li ; Liu, Xiang-Hua ; Liang, Xue ; Zhou, Qing-Lan ; Wu, Da-Peng</creator><creatorcontrib>Ma, Chao ; Nie, Xing-Guo ; Wang, Yan-Li ; Liu, Xiang-Hua ; Liang, Xue ; Zhou, Qing-Lan ; Wu, Da-Peng</creatorcontrib><description>CBX3, namely chromobox protein homolog 3, a member of the heterochomatin protein 1 (HP1) family, has been shown to be associated with the tumorigenesis of various types of cancer. The aim of the present study was to assess the biological role and the clinicopathological importance of CBX3 in osteosarcoma. The Oncomine database was utilized to determine the CBX3 expression in sarcoma patients. A retrospective cohort study was conducted to evaluate the prognostic value of CBX3 expression. In addition, correlations between the clinicopathological features of the osteosarcoma patients and CBX3 expression were assessed and involved recurrence, distant metastasis, lymph node metastasis, response to chemotherapy, pathological differentiation, clinical stage, anatomic location, tumor size and age. To investigate the function of CBX3 in osteosarcoma, a small interfering RNA for CBX3 was designed and this was used for the transfection of osteosarcoma MG63 cells. Then, the effects of CBX3 on proliferation, cell cycle distribution and apoptosis of osteosarcoma cells were investigated via CCK‑8 assay and cell cycle assay and cell apoptosis analysis, respectively. Based on our findings, upregulation of CBX3 expression was noted both in osteosarcoma and also other sarcoma types, which included pleomorphic liposarcoma, myxofibrosarcoma, myxoid/round cell liposarcoma and dedifferentiated liposarcoma. In addition, based on the retrospective cohort study, CBX3 expression was associated with the disease‑free survival (DFS) and overall survival (OS) of the osteosarcoma patients and a large tumor size, high distant metastasis rate and high clinical stage rate. In addition, the proliferation ability was blocked by the knockdown of CBX3 through the application of CBX3 siRNA, and CBX3 knockdown also led to increased apoptosis and cell cycle arrest at G0 and G1 phases in osteosarcoma cells. CBX3 is highly expressed in human osteosarcoma tissues. Meanwhile, high CBX3 is a predictor of the poor prognosis of osteosarcoma patients. To conclude, the growth of osteosarcoma can be promoted by CBX3, which may be used as an independent potential prognostic biomarker for patients suffering from osteosarcoma.</description><identifier>ISSN: 1791-2997</identifier><identifier>EISSN: 1791-3004</identifier><identifier>DOI: 10.3892/mmr.2019.10104</identifier><identifier>PMID: 30942427</identifier><language>eng</language><publisher>Greece: Spandidos Publications</publisher><subject>Age ; Apoptosis ; Bone cancer ; Cancer ; Cancer metastasis ; Cancer research ; Carcinogenesis ; Cell cycle ; Cell growth ; Cell proliferation ; Chemotherapy ; Cholecystokinin ; Confidence intervals ; Diagnosis ; Genetic aspects ; Liposarcoma ; Lymph nodes ; Lymphatic system ; Medical prognosis ; Medical research ; Metastases ; Metastasis ; Mortality ; Multivariate analysis ; Osteosarcoma ; Osteosarcoma cells ; Patient outcomes ; Patients ; Prognosis ; Proteins ; RNA ; Sarcoma ; siRNA ; Studies ; Transfection ; Tumorigenesis ; Tumors</subject><ispartof>Molecular medicine reports, 2019-05, Vol.19 (5), p.4205-4212</ispartof><rights>COPYRIGHT 2019 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2019</rights><rights>Copyright: © Ma et al. 2019</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c551t-72d8451d982c585508e4c9f7a75afae996513196c2137efc1f24aa7982e0b3183</citedby><cites>FETCH-LOGICAL-c551t-72d8451d982c585508e4c9f7a75afae996513196c2137efc1f24aa7982e0b3183</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30942427$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ma, Chao</creatorcontrib><creatorcontrib>Nie, Xing-Guo</creatorcontrib><creatorcontrib>Wang, Yan-Li</creatorcontrib><creatorcontrib>Liu, Xiang-Hua</creatorcontrib><creatorcontrib>Liang, Xue</creatorcontrib><creatorcontrib>Zhou, Qing-Lan</creatorcontrib><creatorcontrib>Wu, Da-Peng</creatorcontrib><title>CBX3 predicts an unfavorable prognosis and promotes tumorigenesis in osteosarcoma</title><title>Molecular medicine reports</title><addtitle>Mol Med Rep</addtitle><description>CBX3, namely chromobox protein homolog 3, a member of the heterochomatin protein 1 (HP1) family, has been shown to be associated with the tumorigenesis of various types of cancer. The aim of the present study was to assess the biological role and the clinicopathological importance of CBX3 in osteosarcoma. The Oncomine database was utilized to determine the CBX3 expression in sarcoma patients. A retrospective cohort study was conducted to evaluate the prognostic value of CBX3 expression. In addition, correlations between the clinicopathological features of the osteosarcoma patients and CBX3 expression were assessed and involved recurrence, distant metastasis, lymph node metastasis, response to chemotherapy, pathological differentiation, clinical stage, anatomic location, tumor size and age. To investigate the function of CBX3 in osteosarcoma, a small interfering RNA for CBX3 was designed and this was used for the transfection of osteosarcoma MG63 cells. Then, the effects of CBX3 on proliferation, cell cycle distribution and apoptosis of osteosarcoma cells were investigated via CCK‑8 assay and cell cycle assay and cell apoptosis analysis, respectively. Based on our findings, upregulation of CBX3 expression was noted both in osteosarcoma and also other sarcoma types, which included pleomorphic liposarcoma, myxofibrosarcoma, myxoid/round cell liposarcoma and dedifferentiated liposarcoma. In addition, based on the retrospective cohort study, CBX3 expression was associated with the disease‑free survival (DFS) and overall survival (OS) of the osteosarcoma patients and a large tumor size, high distant metastasis rate and high clinical stage rate. In addition, the proliferation ability was blocked by the knockdown of CBX3 through the application of CBX3 siRNA, and CBX3 knockdown also led to increased apoptosis and cell cycle arrest at G0 and G1 phases in osteosarcoma cells. CBX3 is highly expressed in human osteosarcoma tissues. Meanwhile, high CBX3 is a predictor of the poor prognosis of osteosarcoma patients. To conclude, the growth of osteosarcoma can be promoted by CBX3, which may be used as an independent potential prognostic biomarker for patients suffering from osteosarcoma.</description><subject>Age</subject><subject>Apoptosis</subject><subject>Bone cancer</subject><subject>Cancer</subject><subject>Cancer metastasis</subject><subject>Cancer research</subject><subject>Carcinogenesis</subject><subject>Cell cycle</subject><subject>Cell growth</subject><subject>Cell proliferation</subject><subject>Chemotherapy</subject><subject>Cholecystokinin</subject><subject>Confidence intervals</subject><subject>Diagnosis</subject><subject>Genetic aspects</subject><subject>Liposarcoma</subject><subject>Lymph nodes</subject><subject>Lymphatic system</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Mortality</subject><subject>Multivariate analysis</subject><subject>Osteosarcoma</subject><subject>Osteosarcoma cells</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Proteins</subject><subject>RNA</subject><subject>Sarcoma</subject><subject>siRNA</subject><subject>Studies</subject><subject>Transfection</subject><subject>Tumorigenesis</subject><subject>Tumors</subject><issn>1791-2997</issn><issn>1791-3004</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNptksuLFDEQxoO4uA-9epQGL15mzLOTXITdwVVhYVlQ8BYy6cqYpZOMSfeC_71pd1wfLDkkVfWrL1TyIfSS4DVTmr6NsawpJnpNMMH8CTohUpMVw5g_PZyp1vIYndZ6i3EvqNDP0DHDmlNO5Qm62Vx8Zd2-wBDcVDubujl5e5eL3Y7Q8nmXcg1LYViimCeo3TTHXMIOEiylkLpcJ8jVFpejfY6OvB0rvDjsZ-jL5fvPm4-rq-sPnzbnVysnBJlWkg6KCzJoRZ1QQmAF3GkvrRTWW9C6F4QR3TtKmATviKfcWtlwwFtGFDtD7-519_M2wuAgTcWOZl9CtOWHyTaYfyspfDO7fGd6LrHWuAm8OQiU_H2GOpkYqoNxtAnyXA2lmPa9wj1p6Ov_0Ns8l9TGaxQhVBGs2B9qZ0cwIfnc7nWLqDlvI3KuhJSNWj9CtTVADC4n8KHlH2twJddawD_MSLBZTGCaCcxiAvPLBK3h1d8v84D__nX2EwzNrGA</recordid><startdate>20190501</startdate><enddate>20190501</enddate><creator>Ma, Chao</creator><creator>Nie, Xing-Guo</creator><creator>Wang, Yan-Li</creator><creator>Liu, Xiang-Hua</creator><creator>Liang, Xue</creator><creator>Zhou, Qing-Lan</creator><creator>Wu, Da-Peng</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190501</creationdate><title>CBX3 predicts an unfavorable prognosis and promotes tumorigenesis in osteosarcoma</title><author>Ma, Chao ; Nie, Xing-Guo ; Wang, Yan-Li ; Liu, Xiang-Hua ; Liang, Xue ; Zhou, Qing-Lan ; Wu, Da-Peng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c551t-72d8451d982c585508e4c9f7a75afae996513196c2137efc1f24aa7982e0b3183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Age</topic><topic>Apoptosis</topic><topic>Bone cancer</topic><topic>Cancer</topic><topic>Cancer metastasis</topic><topic>Cancer research</topic><topic>Carcinogenesis</topic><topic>Cell cycle</topic><topic>Cell growth</topic><topic>Cell proliferation</topic><topic>Chemotherapy</topic><topic>Cholecystokinin</topic><topic>Confidence intervals</topic><topic>Diagnosis</topic><topic>Genetic aspects</topic><topic>Liposarcoma</topic><topic>Lymph nodes</topic><topic>Lymphatic system</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Mortality</topic><topic>Multivariate analysis</topic><topic>Osteosarcoma</topic><topic>Osteosarcoma cells</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Proteins</topic><topic>RNA</topic><topic>Sarcoma</topic><topic>siRNA</topic><topic>Studies</topic><topic>Transfection</topic><topic>Tumorigenesis</topic><topic>Tumors</topic><toplevel>online_resources</toplevel><creatorcontrib>Ma, Chao</creatorcontrib><creatorcontrib>Nie, Xing-Guo</creatorcontrib><creatorcontrib>Wang, Yan-Li</creatorcontrib><creatorcontrib>Liu, Xiang-Hua</creatorcontrib><creatorcontrib>Liang, Xue</creatorcontrib><creatorcontrib>Zhou, Qing-Lan</creatorcontrib><creatorcontrib>Wu, Da-Peng</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular medicine reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ma, Chao</au><au>Nie, Xing-Guo</au><au>Wang, Yan-Li</au><au>Liu, Xiang-Hua</au><au>Liang, Xue</au><au>Zhou, Qing-Lan</au><au>Wu, Da-Peng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CBX3 predicts an unfavorable prognosis and promotes tumorigenesis in osteosarcoma</atitle><jtitle>Molecular medicine reports</jtitle><addtitle>Mol Med Rep</addtitle><date>2019-05-01</date><risdate>2019</risdate><volume>19</volume><issue>5</issue><spage>4205</spage><epage>4212</epage><pages>4205-4212</pages><issn>1791-2997</issn><eissn>1791-3004</eissn><abstract>CBX3, namely chromobox protein homolog 3, a member of the heterochomatin protein 1 (HP1) family, has been shown to be associated with the tumorigenesis of various types of cancer. The aim of the present study was to assess the biological role and the clinicopathological importance of CBX3 in osteosarcoma. The Oncomine database was utilized to determine the CBX3 expression in sarcoma patients. A retrospective cohort study was conducted to evaluate the prognostic value of CBX3 expression. In addition, correlations between the clinicopathological features of the osteosarcoma patients and CBX3 expression were assessed and involved recurrence, distant metastasis, lymph node metastasis, response to chemotherapy, pathological differentiation, clinical stage, anatomic location, tumor size and age. To investigate the function of CBX3 in osteosarcoma, a small interfering RNA for CBX3 was designed and this was used for the transfection of osteosarcoma MG63 cells. Then, the effects of CBX3 on proliferation, cell cycle distribution and apoptosis of osteosarcoma cells were investigated via CCK‑8 assay and cell cycle assay and cell apoptosis analysis, respectively. Based on our findings, upregulation of CBX3 expression was noted both in osteosarcoma and also other sarcoma types, which included pleomorphic liposarcoma, myxofibrosarcoma, myxoid/round cell liposarcoma and dedifferentiated liposarcoma. In addition, based on the retrospective cohort study, CBX3 expression was associated with the disease‑free survival (DFS) and overall survival (OS) of the osteosarcoma patients and a large tumor size, high distant metastasis rate and high clinical stage rate. In addition, the proliferation ability was blocked by the knockdown of CBX3 through the application of CBX3 siRNA, and CBX3 knockdown also led to increased apoptosis and cell cycle arrest at G0 and G1 phases in osteosarcoma cells. CBX3 is highly expressed in human osteosarcoma tissues. Meanwhile, high CBX3 is a predictor of the poor prognosis of osteosarcoma patients. To conclude, the growth of osteosarcoma can be promoted by CBX3, which may be used as an independent potential prognostic biomarker for patients suffering from osteosarcoma.</abstract><cop>Greece</cop><pub>Spandidos Publications</pub><pmid>30942427</pmid><doi>10.3892/mmr.2019.10104</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1791-2997 |
| ispartof | Molecular medicine reports, 2019-05, Vol.19 (5), p.4205-4212 |
| issn | 1791-2997 1791-3004 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6470990 |
| source | Spandidos Publications Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Age Apoptosis Bone cancer Cancer Cancer metastasis Cancer research Carcinogenesis Cell cycle Cell growth Cell proliferation Chemotherapy Cholecystokinin Confidence intervals Diagnosis Genetic aspects Liposarcoma Lymph nodes Lymphatic system Medical prognosis Medical research Metastases Metastasis Mortality Multivariate analysis Osteosarcoma Osteosarcoma cells Patient outcomes Patients Prognosis Proteins RNA Sarcoma siRNA Studies Transfection Tumorigenesis Tumors |
| title | CBX3 predicts an unfavorable prognosis and promotes tumorigenesis in osteosarcoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T20%3A19%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CBX3%20predicts%20an%20unfavorable%20prognosis%20and%20promotes%20tumorigenesis%20in%20osteosarcoma&rft.jtitle=Molecular%20medicine%20reports&rft.au=Ma,%20Chao&rft.date=2019-05-01&rft.volume=19&rft.issue=5&rft.spage=4205&rft.epage=4212&rft.pages=4205-4212&rft.issn=1791-2997&rft.eissn=1791-3004&rft_id=info:doi/10.3892/mmr.2019.10104&rft_dat=%3Cgale_pubme%3EA585448577%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2211281083&rft_id=info:pmid/30942427&rft_galeid=A585448577&rfr_iscdi=true |